BR9813540A - Produtos de condensação de n-benzil-3-indenilacetamidas substituìdos com aldeìdos heterocìclicos para neoplasia - Google Patents

Produtos de condensação de n-benzil-3-indenilacetamidas substituìdos com aldeìdos heterocìclicos para neoplasia

Info

Publication number
BR9813540A
BR9813540A BR9813540-6A BR9813540A BR9813540A BR 9813540 A BR9813540 A BR 9813540A BR 9813540 A BR9813540 A BR 9813540A BR 9813540 A BR9813540 A BR 9813540A
Authority
BR
Brazil
Prior art keywords
indenylacetamides
benzyl
substituted
condensation products
neoplasia
Prior art date
Application number
BR9813540-6A
Other languages
English (en)
Inventor
Gerhard Sperl
Paul Gross
Klaus Brendel
Gary Piazza
Rifat Pamukcu
Original Assignee
Cell Pathways Inc
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/989,353 external-priority patent/US5948779A/en
Application filed by Cell Pathways Inc, Univ Arizona filed Critical Cell Pathways Inc
Publication of BR9813540A publication Critical patent/BR9813540A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>"PRODUTOS DE CONDENSAçãO DE N-BENZIL-3-INDENILACETAMIDAS SUBSTITUìDOS COM ALDEìDOS HETEROCìCLICOS PARA NEOPLASIA"<D>. Os produtos de condensação de N-benzil-3-indenilacetamidas substituídos com aldeídos heterocíclicos são úteis para induzir ou promover apoptose e para deter a proliferação incontrolada de células neoplásticas, e são especificamente úteis para deter e tratar neoplasias, incluindo lesões pré-cancerosas e cancerosas.
BR9813540-6A 1997-12-12 1998-12-11 Produtos de condensação de n-benzil-3-indenilacetamidas substituìdos com aldeìdos heterocìclicos para neoplasia BR9813540A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/989,353 US5948779A (en) 1997-12-12 1997-12-12 Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
US09/206,245 US6066634A (en) 1997-12-12 1998-12-07 Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia
PCT/GB1998/003712 WO1999031065A1 (en) 1997-12-12 1998-12-11 N-benzyl-3-indenylacetamides derivatives for treating neoplasia

Publications (1)

Publication Number Publication Date
BR9813540A true BR9813540A (pt) 2000-10-10

Family

ID=26901185

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813540-6A BR9813540A (pt) 1997-12-12 1998-12-11 Produtos de condensação de n-benzil-3-indenilacetamidas substituìdos com aldeìdos heterocìclicos para neoplasia

Country Status (18)

Country Link
US (3) US6166053A (pt)
EP (1) EP1044187B1 (pt)
JP (1) JP4307719B2 (pt)
CN (1) CN100436418C (pt)
AT (1) ATE257152T1 (pt)
AU (1) AU752072B2 (pt)
BR (1) BR9813540A (pt)
CA (1) CA2314339C (pt)
CZ (1) CZ298826B6 (pt)
DE (1) DE69820908T2 (pt)
ES (1) ES2212383T3 (pt)
HU (1) HU227153B1 (pt)
IL (1) IL136603A0 (pt)
NO (1) NO317097B1 (pt)
NZ (1) NZ504958A (pt)
PL (1) PL196936B1 (pt)
TR (1) TR200001687T2 (pt)
WO (1) WO1999031065A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2314339C (en) * 1997-12-12 2009-09-08 Cell Pathways, Inc. N-benzyl-3-indenylacetamide derivatives for treating neoplasia
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
AU2001255849B8 (en) * 2000-04-19 2006-04-27 Lilly Icos, Llc. PDE-V inhibitors for treatment of Parkinson's Disease
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
WO2002067936A1 (en) * 2001-02-21 2002-09-06 Cell Pathways, Inc. Methods for treatment of inflammatory bowel disease
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
US20030073740A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of lupus erythematosus
CN100398522C (zh) * 2003-08-20 2008-07-02 Irm责任有限公司 组织蛋白酶s的抑制剂
US6995622B2 (en) * 2004-01-09 2006-02-07 Robert Bosh Gmbh Frequency and/or phase compensated microelectromechanical oscillator
JP2008501407A (ja) 2004-06-02 2008-01-24 メリット ダイアモンド コーポレイション 装身具のための快適な内側およびその内側を備える装身具
CN1332930C (zh) * 2005-08-05 2007-08-22 中国科学院上海有机化学研究所 制备乙氰菊酯前体的方法
CN101365461B (zh) * 2006-01-04 2013-07-24 南方研究所 舒林酸衍生物、其用途和其制备
WO2009022756A1 (ja) * 2007-08-13 2009-02-19 Katayama Chemical Industries Co., Ltd. 虚血性疾患の診断及び治療
EP2365746B1 (en) * 2008-11-04 2014-07-16 Wellstat Therapeutics Corporation Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids
WO2011016737A1 (en) 2009-08-07 2011-02-10 Auckland Uniservices Limited Inductive power transfer system
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
JP7169008B2 (ja) 2018-04-26 2022-11-10 エーディーティー ファーマシューティカルズ，エルエルシー 抗がんインデン、インダン、アザインデン、アザインダン、医薬組成物および使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650720B2 (en) * 1991-03-08 1994-06-30 Fgn, Inc. Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
CA2314339C (en) * 1997-12-12 2009-09-08 Cell Pathways, Inc. N-benzyl-3-indenylacetamide derivatives for treating neoplasia
US5948779A (en) * 1997-12-12 1999-09-07 Cell Pathways, Inc. Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes

Also Published As

Publication number Publication date
NO317097B1 (no) 2004-08-09
EP1044187A1 (en) 2000-10-18
CZ298826B6 (cs) 2008-02-20
AU752072B2 (en) 2002-09-05
JP4307719B2 (ja) 2009-08-05
DE69820908T2 (de) 2004-12-23
WO1999031065A1 (en) 1999-06-24
HUP0100170A3 (en) 2001-12-28
EP1044187B1 (en) 2004-01-02
CZ20002157A3 (cs) 2000-10-11
US20030009033A1 (en) 2003-01-09
CA2314339A1 (en) 1999-06-24
DE69820908D1 (de) 2004-02-05
NO20002972L (no) 2000-08-09
JP2002508358A (ja) 2002-03-19
ES2212383T3 (es) 2004-07-16
NO20002972D0 (no) 2000-06-09
CN100436418C (zh) 2008-11-26
ATE257152T1 (de) 2004-01-15
HU227153B1 (en) 2010-08-30
IL136603A0 (en) 2001-06-14
AU1498199A (en) 1999-07-05
US6166053A (en) 2000-12-26
PL196936B1 (pl) 2008-02-29
TR200001687T2 (tr) 2000-10-23
NZ504958A (en) 2003-03-28
CN1281436A (zh) 2001-01-24
CA2314339C (en) 2009-09-08
PL341151A1 (en) 2001-03-26
US6426349B1 (en) 2002-07-30
HUP0100170A1 (hu) 2001-07-30
US6610854B2 (en) 2003-08-26

Similar Documents

Publication Publication Date Title
BR9813540A (pt) Produtos de condensação de n-benzil-3-indenilacetamidas substituìdos com aldeìdos heterocìclicos para neoplasia
BR9805544A (pt) Uso de um composto.
CY1105805T1 (el) Νεος σχηματισμος
BR9814361A (pt) Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila
MY122020A (en) Use of gabab receptor agonists as reflux inhibitors
BR9911781B1 (pt) iluminador para terapia fotodinámica.
ATE320436T1 (de) Dimere pyrrolobenzodiazepine
NO995242D0 (no) Adenovirusmediert intratumoravlevering av en angiogeneseantagonist for behandling av tumorer
HK1048468A1 (en) Indole derivatives and their use for the treatmentof osteoporosis amongst other applications.
BR0015490A (pt) Combinações oncolìticas para o tratamento de câncer
BR9807655A (pt) Uso de inibidores de lipase gastrintestinal.
TR199800270T1 (xx) Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
AR016981A2 (es) Polipeptidos sinteticos
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
BR9702557B1 (pt) composição farmacêutica para o tratamento de neoplasias malignas e processo para fabricação de uma composição farmacêutica para o tratamento de neoplasias malignas.
ID24283A (id) Turunan-turunan asam karboksilat baru, pembuatannya dan penggunaannya dalam pengobatan kanker
ATE218881T1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
ITBO970367A0 (it) Macchina operatrice, e relativo procediemento, per la lavorazione di corpi piani.
BR1100326A (pt) Microemulsão para o tratamento e diagnóstico de neoplasias malignas
BR9814114A (pt) Uso de quinapril para o tratamento de isquemia miocárdica e angina
IT1295702B1 (it) Procedimento per la trasformazione di materiali di scarto.
NO963870D0 (no) Vanadatforbindelser for behandling av proliferative forstyrrelser, metastaser og medikamentresistente tumorer
ES1044437Y (es) Pieza para la formacion de lamparas.
ES1038154Y (es) Dispositivo para la determinacion del contenido en carbonatos.
IT1313038B1 (it) Procedimento per la realizzazione di carta goffrata, in particolaredel tipo impiegato per l&#39;ottenimento di prodotti o materiali spalmati,

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: THE UNIVERSITY OF ARIZONA (US), OSI PHARMACEUTICALS, INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O, 10,13, 24 E 25 DA LPI